Vectorite Biomedical, Inc. Statistics
Vectorite Biomedical, Inc. (4170) Stock Statistics & Valuation Metrics
Total Valuation
Vectorite Biomedical, Inc. has a market cap or net worth of TWD 481.49M. The enterprise value is ―.
- Market Cap
- TWD 481.49M
- Enterprise Value
- ―
Share Statistics
Vectorite Biomedical, Inc. has 43,771,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,771,370
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Vectorite Biomedical, Inc.’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is -4.44%.
- Return on Equity (ROE)
- 0.20
- Return on Assets (ROA)
- 0.19
- Return on Invested Capital (ROIC)
- -4.44%
- Return on Capital Employed (ROCE)
- -0.04
- Revenue Per Employee
- 1.43M
- Profits Per Employee
- 2.24M
- Employee Count
- 43
- Asset Turnover
- 0.12
- Inventory Turnover
- 2.65
Valuation Ratios
The current PE Ratio of Vectorite Biomedical, Inc. is 4.07. Vectorite Biomedical, Inc.’s PEG ratio is 0.01.
- PE Ratio
- 4.07
- PS Ratio
- 8.78
- PB Ratio
- 0.94
- Price to FCF
- -57.55
- Price to Operating Cash Flow
- -101.33
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Vectorite Biomedical, Inc. had revenue of 61.41M and earned 96.14M in profits. Earnings per share was 2.20.
- Revenue
- 61.41M
- Gross Profit
- 21.68M
- Operating Income
- -21.91M
- Pretax Income
- 96.14M
- Net Income
- 96.14M
- EBITDA
- -13.77M
- Earnings Per Share (EPS)
- 2.20
Cash Flow
In the last 12 months, operating cash flow was -4.76M and capital expenditures -3.61M, giving a free cash flow of -8.37M billion.
- Operating Cash Flow
- -4.76M
- Free Cash Flow
- -8.37M
- Free Cash Flow per Share
- -0.19
Dividends & Yields
Vectorite Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.75%
- Earnings Yield
- 24.61%
Stock Price Statistics
- Beta
- 0.28
- 52-Week Price Change
- -21.99%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 24.78
- Average Volume (3m)
- 27.83K
Financial Position
Vectorite Biomedical, Inc. as a current ratio of 11.85, with Debt / Equity ratio of 0.08%
- Current Ratio
- 11.85
- Quick Ratio
- 10.93
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.84
- Interest Coverage Ratio
- -1991.64
Taxes
In the past 12 months, Vectorite Biomedical, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vectorite Biomedical, Inc. EV to EBITDA ratio is -28.66, with an EV/FCF ratio of -54.76.
- EV to Sales
- 8.36
- EV to EBITDA
- -28.66
- EV to Free Cash Flow
- -54.76
- EV to Operating Cash Flow
- -96.24
Balance Sheet
Vectorite Biomedical, Inc. has TWD 166.32M in cash and marketable securities with TWD 298.00K in debt, giving a net cash position of TWD 166.02M billion.
- Cash & Marketable Securities
- TWD 166.32M
- Total Debt
- TWD 298.00K
- Net Cash
- TWD 166.02M
- Net Cash Per Share
- TWD 3.79
- Tangible Book Value Per Share
- TWD 11.64
Margins
Gross margin is 31.09%, with operating margin of -42.29%, and net profit margin of 215.64%.
- Gross Margin
- 31.09%
- Operating Margin
- -42.29%
- Pretax Margin
- 219.70%
- Net Profit Margin
- 215.64%
- EBITDA Margin
- -29.17%
- EBIT Margin
- -42.29%
Analyst Forecast
The average price target for Vectorite Biomedical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -19.28%
- EPS Growth Forecast
- ―
